Several studies have indicated beneficial effects of glucagon-like peptide 1 (GLP-1) receptor agonists (GLP-1RA) on NAFLD and NASH [11,12,13,14,15,16,17,18,19,20,21,22,23,24,25]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.